Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
We’re here in STAT’s Brooklyn outpost today, where everyone’s gazing across the East River to see whether Pfizer’s former ...
Sarah covers how industries like food and tobacco affect Americans’ bodies and minds. Her interests include ultra-processed foods; smoke-free tobacco; and wellness trends like perimenopause products ...
It’s time to bring production of essential medications back to the U.S. — or at least closer to home. The meeting, described ...
Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Prime Medicine said Wednesday that it had ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout ...
America's employer-based health insurance system is crumbling. STAT investigates why, in our new series, “Out of Pocket, Out ...
Read the 5 key takeaways from STAT's series "Out of Pocket, Out of Reach," an examination of workplace health insurance.
A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical ...
America’s employers must stop acting helpless in the face of health care industry profiteering, Chris Deacon says.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results